Related by context. All words. (Click for frequent words.) 76 androgen suppression 74 androgen suppression therapy 73 adjuvant radiotherapy 73 EBRT 73 curative resection 72 preoperative chemotherapy 72 clinically localized prostate 72 mycophenolate mofetil 72 androgen ablation 71 cystectomy 71 chemoradiotherapy 71 prostate cancer CaP 71 biochemical recurrence 71 corticosteroid therapy 71 ALND 71 recurrent VTE 70 GnRH agonists 70 neoadjuvant 70 neoadjuvant chemotherapy 70 Adjuvant chemotherapy 70 neoadjuvant therapy 70 lymph node dissection 70 nonoperative treatment 70 postoperative chemotherapy 70 antithrombotic therapy 70 aromatase inhibitor therapy 70 androgen deprivation therapy 70 adjuvant therapy 69 prostate cancer CRPC 69 adjuvant radiation 69 hematologic toxicity 69 Radical prostatectomy 69 cytoreduction 69 pCR 69 cisplatin chemotherapy 69 GnRH agonist 69 debulking surgery 69 pelvic lymphadenectomy 69 cranial irradiation 69 imatinib therapy 69 endometrial carcinoma 69 surgical debulking 69 beta blocker therapy 69 chemoradiation 69 LHRH agonists 69 biochemical relapse 69 nonmetastatic prostate cancer 69 locoregional 69 virological response 68 perioperative morbidity 68 external beam radiotherapy 68 radical prostatectomy RP 68 PSADT 68 postoperative radiotherapy 68 thromboembolic events 68 intravenous bisphosphonates 68 asymptomatic carotid stenosis 68 orchiectomy 68 perioperative complications 68 cytoreductive surgery 68 β blockers 68 thromboembolic complications 68 postoperative mortality 68 NATRECOR ® 68 undergoing radical prostatectomy 68 hepatic metastases 67 PSA nadir 67 paroxysmal AF 67 adriamycin 67 recurrent glioblastoma multiforme 67 lymphadenectomy 67 metastatic RCC 67 Doxil ® 67 fibrinolysis 67 methotrexate therapy 67 HNSCC 67 cranial radiation 67 immunosuppressive regimen 67 carotid IMT 67 antiandrogens 67 pneumonectomy 67 bisphosphonate therapy 67 leiomyomas 67 lenalidomide dexamethasone 67 clodronate 67 goserelin 67 amenorrhoea 67 thromboembolic 67 anticoagulation therapy 67 prostate cancer PCa 67 flutamide 67 CTEPH 67 adrenal suppression 67 myeloablative 67 immunosuppressive medications 67 neoplasia 67 antiarrhythmic drugs 67 post thrombotic syndrome 67 tumor recurrence 67 antiandrogen 67 hemorrhagic complications 67 anthracycline containing 67 TNF antagonist 67 serum calcium levels 67 thrombotic complications 67 renal tumors 67 bilateral oophorectomy 66 symptomatic VTE 66 oophorectomy 66 tamoxifen therapy 66 endometrial hyperplasia 66 postoperative AF 66 AGILECT R 66 thromboprophylaxis 66 pamidronate 66 adjuvant therapies 66 mg kg dose 66 CIN3 66 gemcitabine Gemzar 66 cytotoxic chemotherapy 66 dopaminergic therapy 66 virologic failure 66 systemic corticosteroid 66 Adjuvant therapy 66 severe neutropenia 66 cerebrovascular events 66 neurocognitive function 66 prostate adenocarcinoma 66 radiochemotherapy 66 bone metastasis 66 urothelial carcinoma 66 stage IIIB 66 warfarin therapy 66 morphometric vertebral fractures 66 subclinical hypothyroidism 66 paclitaxel eluting stents 66 relapsed ovarian cancer 66 immunosuppressive agents 66 colorectal adenoma 66 thromboembolism 66 neurologic progression 66 hormonal therapy 66 antioxidant supplementation 66 pancreatic adenocarcinoma 66 nonmelanoma skin cancers 66 advanced adenomas 66 NNRTI resistance 66 AVODART 66 immunosuppression 66 FOLFOX4 66 androgen deficiency 66 resectable 66 prednisone prednisolone 66 prostate carcinoma 66 Androgen deprivation therapy 66 adjuvant tamoxifen 66 5-fluorouracil/leucovorin 66 salpingo oophorectomy 66 etiologic 66 testosterone supplementation 66 PCa 66 medically inoperable 66 aminotransferases 66 NMIBC 66 APTIVUS r 66 ipsilateral stroke 66 operable breast cancer 65 intravesical therapy 65 CsA 65 fulvestrant 65 adrenalectomy 65 LNG IUS 65 levodopa therapy 65 hyperalgesia 65 hormone deprivation 65 glucocorticoid therapy 65 LV hypertrophy 65 ovariectomy 65 reinfarction 65 skeletal metastases 65 adenomatous polyps 65 serum testosterone 65 BRCA2 mutation carriers 65 nonoperative 65 T2DM 65 Hurthle cell 65 relapsed MM 65 EXJADE 65 chemotherapeutic regimens 65 mTOR inhibitors 65 neoplasias 65 virologic response 65 locoregional recurrence 65 liver metastasis 65 pegylated liposomal doxorubicin 65 rFVIIa 65 HER2 overexpression 65 carotid stenosis 65 oncologic outcomes 65 HBeAg negative 65 transurethral resection 65 distant metastases 65 antithymocyte globulin 65 interferon therapy 65 conventional angiography 65 idarubicin 65 Leydig cell 65 riociguat 65 radioiodine therapy 65 tumor necrosis 65 Thal Dex 65 underwent resection 65 anthracycline therapy 65 endocrine therapies 65 intraoperative complications 65 oral anticoagulation 65 taxane therapy 65 recurrent prostate cancer 65 F FDG PET 65 nephron sparing surgery 65 seminoma 65 breast carcinoma 65 acute GvHD 65 cytotoxic therapy 65 tumor resection 65 intravenous cyclophosphamide 65 metastatic neuroendocrine tumors 65 5FU 65 5-FU/LV 65 dexrazoxane 65 sleeve lobectomy 65 unresectable tumors 65 alteplase 65 recurrent myocardial infarction 65 OAB symptoms 65 Surgical resection 65 Cardiopulmonary bypass 65 platelet reactivity 65 subtrochanteric 65 postoperative morbidity 65 biologic DMARD 65 perioperative mortality 65 radical cystectomy 65 Natalizumab 65 postoperative complication 65 nonfatal MI 65 chemoradiation therapy 65 Kaplan Meier analysis 65 anthracycline taxane 65 hepatocellular carcinomas 65 T1DM 65 antiangiogenic therapy 65 LUTS 65 decompensated cirrhosis 65 radiotherapy RT 65 vaginal hysterectomy 65 CMV infection 65 advanced adenoma 65 palliation 65 liver resection 64 peritoneal carcinomatosis 64 lymphocytosis 64 Subgroup analysis 64 Heavy menstrual bleeding 64 adjuvant chemotherapy 64 mRCC 64 antiarrhythmic medications 64 LHRH receptor positive 64 nonmetastatic 64 DAPT 64 pathologic fractures 64 parathyroidectomy 64 carcinoids 64 nonischemic 64 perioperatively 64 pyridostigmine 64 paricalcitol 64 K ras mutations 64 tibolone 64 multivariate Cox 64 efalizumab 64 methotrexate monotherapy 64 neurocognitive deficits 64 invasive aspergillosis 64 radical prostatectomy 64 kidney allograft 64 overlapping toxicities 64 metastatic malignant melanoma 64 bladder carcinoma 64 HoLEP 64 estramustine 64 sorafenib Nexavar 64 standard chemotherapy regimens 64 histologically confirmed 64 decitabine 64 pulmonary dysfunction 64 antimicrobial prophylaxis 64 myocardial ischemia 64 allogeneic HSCT 64 DMARD 64 cytoreductive nephrectomy 64 proliferative retinopathy 64 pulmonary exacerbations 64 loop diuretics 64 definite stent thrombosis 64 polyp recurrence 64 pelvic radiotherapy 64 adnexal mass 64 immune reconstitution 64 bone marrow suppression 64 posaconazole 64 coadministration 64 antiarrhythmic drug 64 adenoma recurrence 64 virologic responses 64 chorioamnionitis 64 endometrial thickness 64 radical nephrectomy 64 malignant neoplasms 64 lung metastasis 64 hormonal therapies 64 metastatic castration resistant 64 cabazitaxel 64 IV bisphosphonates 64 ICD shocks 64 platelet inhibitor 64 pheochromocytoma 64 Surgical excision 64 allogeneic SCT 64 LHRH agonist 64 concurrent chemoradiation 64 hypercalcemia 64 rebleeding 64 Venous thromboembolism 64 graft dysfunction 64 lipid lowering agents 64 allogeneic stem cell 64 epirubicin 64 MGd 64 sulfasalazine 64 PAOD 64 reperfusion therapy 64 nodal metastases 64 antidepressant therapy 64 dose cytarabine 64 revascularization procedures 64 varicoceles 64 metastatic lung cancer 64 coronary revascularization 64 nephrectomy 64 opioid analgesia 64 CR nPR 64 ischemic cardiomyopathy 64 cervical lesions 64 osteopenic 64 precursor lesions 64 contralateral breast 64 pelvic lymph node dissection 64 busulfan 64 denervation 64 recurrent DVT 64 serum PSA 64 azoospermia 64 hematopoietic cancers 64 colorectal liver metastases 64 hippocampal atrophy 64 intestinal metaplasia 64 hypoglycemic episodes 64 Neoadjuvant 64 Chronic pancreatitis 64 weekly subcutaneous injections 64 extrapyramidal symptoms 64 metaplasia 64 antiemetics 64 TNF blocker therapy 64 HMG CoA reductase inhibitors 64 ximelagatran 64 extrapyramidal symptoms EPS 64 selenium supplementation 64 thiazide diuretic 64 hepatic resection 64 immunomodulatory therapy 64 poorer prognosis 64 MACCE 64 systemic corticosteroids 64 Combination therapy 64 transarterial chemoembolization 64 colorectal carcinoma 64 LV dysfunction 64 neoadjuvant treatment 64 CMV disease 64 sustained virological response 64 HbF 64 lipid lowering therapy 64 postoperative atrial fibrillation 64 gadolinium enhanced 64 DMARDs 64 proximal DVT 64 adrenal insufficiency 64 pulmonary metastases 64 R0 resection 64 tamoxifen Nolvadex ® 64 heavily pretreated 64 serum estradiol 64 Flu Cy 64 periprocedural 64 overactive bladder symptoms 64 T1c 64 Postoperative complications 64 PHPT 64 FOLFIRI 64 argatroban 64 Helicobacter pylori eradication 64 bezafibrate 64 folinic acid 64 KRAS status 64 mCRC patients 63 seminomas 63 variceal hemorrhage 63 hyperprolactinemia 63 trastuzumab Herceptin ® 63 STRIDE PD 63 anemia hemoglobin 63 MGUS 63 pharmacologic intervention 63 ischemic lesions 63 invasive candidiasis 63 thalidomide dexamethasone 63 neutropenic patients 63 chemoembolization 63 metastatic gastric 63 bowel resection 63 intratumoral 63 TACE 63 6 mercaptopurine 63 anastrozole 63 prospectively defined 63 tumor regressions 63 renal dysfunction 63 Severe Primary IGFD 63 ADPKD 63 minimally symptomatic 63 anti androgen 63 ovarian hormones 63 postoperative pulmonary 63 caspofungin 63 lymph node removal 63 virological failure 63 octreotide LAR 63 histologic subtype 63 lymph node metastasis 63 liver metastases 63 prognostic variables 63 inotropic 63 QTc prolongation 63 cytopenias 63 tocilizumab 63 Cystectomy 63 urothelial cancer 63 thrombolytic agents 63 TEAEs 63 IV NSCLC 63 posttransplant 63 H. pylori eradication 63 TNF inhibitor 63 Subgroup analyzes 63 oral anticoagulant therapy 63 fallopian tube cancers 63 glycated hemoglobin levels 63 androgen therapy 63 IFN beta 63 doxorubicin docetaxel 63 invasive coronary angiography 63 dosage regimens 63 node metastases 63 sustained ventricular tachycardia 63 HBeAg 63 elevated transaminases 63 micrometastases 63 symptomatic paroxysmal AF 63 DMARD therapy 63 malignant neoplasm 63 PASI scores 63 bicalutamide 63 metachronous 63 erlotinib Tarceva 63 fibrinolytic therapy 63 proliferative diabetic retinopathy 63 comorbid conditions 63 colorectal cancer liver metastases 63 baseline LDH 63 ribavirin therapy 63 neutrophil counts 63 neoplastic lesions 63 amenorrhea 63 cyclophosphamide 63 nephrotoxicity 63 haematological toxicity 63 atherogenic dyslipidemia 63 hepatotoxicity 63 Hydroxyurea 63 mutated KRAS 63 SLNB 63 thyroid carcinoma 63 sirolimus eluting stents 63 curative therapy 63 hypogonadotropic hypogonadism 63 QTc intervals 63 GISTs 63 neurodevelopmental impairment 63 neoadjuvant radiation 63 cardiotoxicity 63 metastatic bladder 63 cerebral vasospasm 63 systemic toxicity 63 neurologic deficits 63 HBeAg positive patients 63 progression TTP 63 taxane chemotherapy 63 serum phosphate 63 axillary node dissection 63 perfusion abnormalities 63 platelet inhibition 63 MAGE A3 ASCI 63 leiomyoma 63 adalimumab 63 aldosterone antagonists 63 catheter angiography 63 myocardial reperfusion 63 premalignant 63 HBeAg seroconversion 63 pT2 63 IDH mutations 63 CP CPPS 63 unstable angina UA 63 lymphadenopathy 63 gonadotropin releasing hormone 63 adenotonsillectomy 63 haematologic 63 femoral neck fracture 63 axillary node 63 FASLODEX 63 recurrent venous thromboembolism 63 TTF Therapy 63 olmesartan 63 intact parathyroid hormone 63 undergoing coronary angiography 63 carboplatin paclitaxel 63 CIMZIA ™ 63 detrusor overactivity 63 metastatic lesions 63 endometrial cancers 63 daunorubicin 63 liver biopsies 63 unresectable stage 63 intravitreal injections 63 imatinib Gleevec 63 mycophenolate mofetil MMF 63 hormone refractory 63 ventricular tachyarrhythmias 63 therapeutic regimens 63 epithelial tumors 63 orchitis 63 fluvastatin 63 somatostatin analogs 63 clinicopathological features 63 chronic periodontitis 63 osteochondromas 63 NATRECOR R 63 variceal bleeding 63 prognostic indicator 63 intensive statin therapy 63 sentinel lymph node biopsy 63 nadolol 63 castrate resistant 63 carcinoid tumor 63 EGFR tyrosine kinase inhibitors 63 colorectal neoplasms 63 transplantation HCT 63 immunosuppressive medication 63 androgen blockade 63 distant metastasis 63 Pemetrexed 63 NPH insulin 63 peginterferon 63 ventricular tachyarrhythmia 63 renal scarring 63 cisplatin resistant 63 tolterodine 63 pT3 63 non squamous NSCLC 63 Tavocept 63 stage IIIb IV 63 advanced hepatocellular carcinoma 63 BEACOPP 63 KRAS mutations occur 63 varices 63 CLA supplementation 62 antibiotic prophylaxis 62 leukemia AML 62 temsirolimus 62 VT VF 62 anti leukemic 62 verteporfin 62 intima media thickness 62 varicocele 62 cardiac dysfunction 62 chemo radiotherapy 62 aldosterone antagonist 62 left ventricular dysfunction 62 non progressors 62 transgene expression 62 ductal breast cancer 62 meniscectomy 62 serum creatinine levels 62 osteosarcomas 62 myelosuppression 62 atypical antipsychotic medications 62 metabolic parameters 62 NSTEMI 62 fallopian tube carcinoma 62 nodal metastasis 62 corticosteroid dose 62 atrophic gastritis 62 CVD mortality 62 atherothrombotic disease 62 metastatic malignant 62 recurrent NSCLC 62 thromboembolic disease 62 mitoxantrone chemotherapy 62 thymoma 62 QTc interval 62 prostate TURP 62 noncardiac 62 intracranial stenosis 62 concomitant medications 62 lethal arrhythmias 62 histological subtype 62 intraventricular hemorrhage 62 FOLFOX6 62 undergo radical prostatectomy 62 malignant pleural mesothelioma 62 FIRMAGON 62 neurologic sequelae 62 oral clodronate 62 antiplatelet therapy 62 mitoxantrone 62 metastatic hormone refractory 62 TMP SMX 62 androgen independent 62 lumbar spine BMD 62 complete cytogenetic response 62 XELOX 62 sentinel node biopsy 62 pulmonary artery hypertension 62 cidofovir 62 moderate renal impairment 62 mutated K ras 62 genotypic resistance 62 lichen planus 62 nucleoside naive patients 62 gemcitabine chemotherapy 62 vinorelbine 62 metastatic GIST 62 renal flares 62 bronchopulmonary dysplasia 62 paclitaxel Taxol 62 papillary renal cell carcinoma 62 direct thrombin inhibitors 62 nonpharmacologic 62 thrombocytosis 62 upper gastrointestinal bleeding 62 TP# mutations 62 pentoxifylline 62 chlamydial infection 62 atypical ductal hyperplasia 62 IL 1ß 62 chronic GVHD 62 Lenalidomide 62 corifollitropin alfa 62 cervical lymph nodes 62 low dose cytarabine 62 neurologic complications 62 gastric carcinoma 62 aromatase inhibitors AIs 62 posttreatment 62 microsatellite instability 62 DHEA supplementation 62 surgical revascularization 62 basal cell carcinoma BCC 62 specific antigen PSA 62 Paraplatin ® 62 complement inhibitor eculizumab 62 nonvertebral fractures 62 BEXXAR Therapeutic Regimen 62 T1a 62 depressive symptomatology 62 tamsulosin 62 adenomatous 62 alkylating agent 62 advanced neoplasia 62 Toxicities 62 Platinol ® cisplatin 62 colorectal adenomas 62 recurrent GBM 62 EGFR inhibitors 62 ovarian carcinoma 62 hemodilution 62 everolimus eluting stents 62 FROVA 62 cystic lesions 62 neoplasm 62 chlamydial 62 L dopa 62 superficial bladder cancer 62 antiangiogenic agents 62 paroxetine Paxil 62 pulmonary artery banding 62 ICD implantation 62 lumbar disk herniation 62 antihypertensive therapy 62 chemotherapy docetaxel 62 Mitomycin C 62 erlotinib Tarceva ® 62 plasma uric acid 62 fluorouracil 62 disease progression 62 lymph node involvement 62 ovarian suppression 62 osteoporotic vertebral compression fractures 62 BCG refractory 62 CYPHER Stent 62 thrombotic events 62 angiographically 62 resynchronization therapy 62 taxane resistant 62 chemosensitivity 62 heavily pretreated patients 62 hepatocellular 62 Elitek 62 nonvertebral fracture 62 axillary lymph node dissection 62 orchidectomy 62 epithelial ovarian cancer 62 standard chemotherapy regimen 62 VTE prophylaxis 62 urinary symptoms 62 remyelination 62 anticoagulant therapy 62 elevated CRP 62 eplerenone 62 PREZISTA r 62 Degarelix 62 coronary stenosis 62 invasive carcinoma 62 GIST tumors 62 CHOP chemotherapy 62 liver histology 62 androgen ablation therapy 62 colectomy 62 ABVD 62 prostate carcinogenesis 62 DFMO 62 Ovary removal 62 differentiated thyroid 62 nonmyeloablative 62 vasomotor symptoms 62 periprocedural MI 62 vasospasm 62 thyrotropin levels 62 radiographic progression 62 Mitoxantrone 62 interferon alfa 62 nondiabetic patients 62 iodixanol 62 HSCT 62 pulmonary resection 62 hydroxychloroquine 62 myeloproliferative diseases 62 variceal 62 inhaled budesonide 62 idraparinux 62 thrombolytic therapy 62 DOXIL 62 dexamethasone Decadron 62 PNH patients 62 induce remission 62 corrected QT interval 62 cancer mCRC 62 acute aortic dissection 62 fondaparinux 62 hypogonadal 62 EDSS scores 62 atypical hyperplasia 62 bleomycin 62 Fludarabine 62 transaminase elevations 62 adjuvant cisplatin 62 RAS blockers 62 graft occlusion 62 Anthracycline 62 HGPIN 62 angiotensin converting enzyme inhibitors 62 histologically proven 62 aneurysm rupture 62 IELT 62 ventricular tachycardia VT 62 timepoints 62 adenoma 62 thrombocytopenic 62 tipranavir ritonavir 62 relapsed AML 62 metastatic renal cell carcinoma 62 postoperative bleeding 62 relapsed SCLC 62 SRBD 62 ventricular fibrillation VF 62 serum concentrations 62 neoplastic 62 recurrent metastatic 62 hormone therapy estrogen 62 pharmacological interventions 62 hypopituitarism 62 LHRH 62 concomitant AEDs 62 gastric adenocarcinoma 62 IOP lowering 62 cisplatin gemcitabine 62 #Gy 62 venous thromboembolic events 62 abiraterone acetate 62 abnormal Pap smears 62 tumor shrinkage 62 KRAS mutations 62 myocardial infarction MI 62 pathologic fracture 62 Barrett esophagus BE 62 antiplatelet drugs 62 vandetanib 62 alpha interferons 62 fluoropyrimidine 62 chlorambucil 62 pharmacokinetic interactions 62 bexarotene 62 premalignant lesions 62 CIMZIA TM certolizumab pegol 62 prophylactic oophorectomy 62 p = NS 61 menopausal symptom 61 exemestane 61 azacitidine 61 transthoracic 61 elevated LDH 61 HER2 negative 61 psychiatric comorbidity 61 CCyR 61 serum HBV DNA 61 prognostic factors 61 castrate resistant prostate cancer 61 lipid lowering therapies 61 pyrazinamide 61 calcineurin inhibitor 61 euthyroid 61 neurocognitive impairment 61 cilostazol 61 preoperative PSA 61 GP IIb IIIa inhibitors 61 visilizumab 61 NAbs 61 docetaxel chemotherapy 61 renal cell carcinomas 61 hormone receptor negative 61 thyrotropin 61 artery stenosis 61 incomplete revascularization 61 reoperations 61 Subarachnoid hemorrhage 61 cerebral infarction 61 microvascular complications 61 partial nephrectomy 61 spontaneous preterm delivery 61 steatohepatitis 61 zoledronic acid 61 ibandronate 61 hip resurfacing arthroplasty 61 ALA PDT 61 allogeneic transplantation 61 placebo dexamethasone 61 antitumor efficacy 61 trans retinoic acid 61 ASCUS 61 hypoxemia 61 radical retropubic prostatectomy 61 Febrile neutropenia 61 arteriography 61 CTAP# Capsules 61 Hypotension 61 serum testosterone levels 61 breast endometrial 61 interferon IFN 61 overt hypothyroidism 61 endosonography 61 interferon ribavirin 61 patients undergoing CABG 61 infliximab 61 adenoidectomy 61 sustained virologic response 61 FOLFIRINOX 61 repolarization 61 sotalol 61 neurological sequelae 61 systolic hypertension 61 cis retinoic acid 61 Radiofrequency ablation 61 neurologic outcomes 61 myelosuppressive 61 spontaneous bacterial peritonitis 61 pericardial effusion 61 undergone radical prostatectomy 61 GH deficiency 61 Decitabine 61 Torisel 61 HER2 expression 61 prior chemotherapy regimens 61 bendamustine 61 acetabular dysplasia 61 clomipramine 61 prognostic indicators 61 aspirin clopidogrel 61 Bezielle 61 serous ovarian cancer 61 postmenopausal estrogen 61 renal allograft 61 intraventricular 61 grade cervical intraepithelial 61 death reinfarction 61 metastatic disease 61 P = .# 61 thromboses 61 TNF α 61 acute coronary syndromes ACS 61 choroidal neovascularization 61 revascularizations 61 leukocytosis 61 relapsing remitting MS RRMS 61 mucinous 61 recurrent glioblastoma 61 multivariable Cox 61 conjugated equine estrogen 61 urography 61 unresectable 61 HBV infection 61 adjuvant hormonal therapy 61 elevated serum creatinine 61 precancerous cervical lesions 61 ALT flares 61 typical antipsychotics 61 impair fertility 61 hormonal treatments 61 dose dexamethasone 61 Recurrences 61 bronchogenic carcinoma 61 epithelial ovarian 61 squamous cell carcinoma SCC 61 durable remissions 61 TroVax ® 61 arterial calcification 61 urate lowering therapy 61 hamartomas 61 ertapenem 61 refractory ischemia 61 mycophenolate 61 atherosclerotic disease 61 nephrotoxic 61 basal cell nevus syndrome 61 Candida infection 61 parathyroid 61 unruptured aneurysm 61 calcineurin inhibitors 61 severe exacerbations 61 trimethoprim sulfamethoxazole 61 cerebral ischemia 61 antiarrhythmic 61 seropositive patients 61 axillary dissection 61 torsade de pointes 61 liver transplant recipients 61 cerebral angiography 61 inhaled bronchodilators 61 etanercept 61 HPA axis suppression 61 Hormonal therapy 61 Platinol ® 61 HBeAg positive 61 claudication 61 octreotide 61 neuropsychiatric symptoms 61 benign prostatic hypertrophy 61 mitochondrial toxicity